Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Company
Actavis plc operates as an investment holding company.It is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand, brand generic, over-the-counter and biosimilar products.The company was founded on October 1, 2013 and is... 
Sector
Pharmaceuticals
Calendar
03/10 | 03:30amShareholder meeting
More about the company
Surperformance© ratings of Actavis Inc
Trading Rating : Investor Rating :
More Ratings
Financials ($)
Sales 2015 21 034 M
EBIT 2015 8 468 M
Net income 2015 4 609 M
Debt 2015 17 020 M
Yield 2015 -
Sales 2016 24 965 M
EBIT 2016 11 609 M
Net income 2016 4 945 M
Debt 2016 29 953 M
Yield 2016 -
PER 2015 27,17
PER 2016 18,68
EV / Sales 2015 4,68x
EV / Sales 2016 4,46x
Capitalization 81 444 M
More Financials
Latest news on ACTAVIS INC
02/27 ACTAVIS : Novan Expands Leadership Team with Vice President of Regulatory Affair..
02/27 AstraZeneca to carve out antibiotic R&D into separate firm
02/26 ACTAVIS : Launches Generic Pulmicort RESPULES®
02/26 ACTAVIS : Announces Intention to Adopt "Allergan" Corporate Name
02/25 ALLERGAN : Actavis Announces Proposed Public Offerings of Ordinary Shares and Ma..
02/25 ACTAVIS : FDA approves new antibiotic combo from Actavis
02/25 ACTAVIS : Receives U.S. FDA Approval for AVYCAZ(TM) (CEFTAZIDIME-AVIBACTAM)
02/25 ACTAVIS : Non-GAAP Net Revenue Increases 44% to $4 Billion in Fourth Quarter 201..
More news
Sector news Pharmaceuticals - NEC
09:38a PFIZER : Groton Board of Education submits $77.1 million budget
09:38a PFIZER : Big-time research on a small campus
06:03aDJMARKET SNAPSHOT : Jobs Report Key For Investors In Week Ahead
Plus d'actualités du secteur Pharmaceuticals - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF